Xenetic Biosciences (XBIO)

• Market cap: $4.67M
• 1 day: -5.61%
• 5 days: -2.72%
• 1 month: -20.56%
• 3 months: -0.69%
• 6 months: -28.14%
• Year to date: -29.38%
• 1 year: -31.08%
• 5 years: -74.69%
• 10 years: -99.43%
• Sector: Healthcare
• Industry: Biotechnology

About: Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.

Employees: 2

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

2.82% less ownership

Funds ownership: 6.98% [Q1] → 4.16% (-2.82%) [Q2]

15% less capital invested

Capital invested by funds: $293K [Q1] → $250K (-$43.3K) [Q2]

31% less funds holding

Funds holding: 13 [Q1] → 9 (-4) [Q2]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3